A 30-year-old pregnant woman (G2P1) at 36 weeks of gestation comes to the pediatric clinic for a prenatal consultation. She has a known history of Graves' disease (hyperthyroidism) diagnosed 5 years ago. She is currently on propylthiouracil (PTU) 100 mg twice daily. Her thyroid function tests (TFTs) have been suboptimally controlled during pregnancy, with a recent TSH <0.01 mIU/L and free T4 elevated. She is very anxious and asks:
"Doctor, I am due to deliver in a few weeks. I am very worried about my baby. Will my baby also have thyroid problems? Can the medicine I take harm my baby? Will my baby need treatment after birth? Can I breastfeed while taking PTU? Please tell me everything."
She has no other medical issues. Her first child (now 4 years old) was healthy and had no thyroid problems. The father is healthy with no thyroid disease.
Task for the candidate: You are the pediatrician. Counsel the mother about the risk of neonatal hyperthyroidism (neonatal thyrotoxicosis) due to transplacental passage of TSH receptor antibodies (TRAb), the effects of antithyroid drugs (PTU/methimazole) on the fetus/neonate, the importance of newborn screening and monitoring, management of neonatal thyrotoxicosis, and breastfeeding safety. The examiner will observe your interaction and communication skills.
💡 Examiner instruction (interactive – observed counseling):
• The candidate must demonstrate empathy, active listening, and clear communication.
• Use simple, non-technical language initially, then introduce terms appropriately.
• Address the mother's anxiety first ("Your concerns are very valid. We will make a plan to protect your baby").
• Explain: Neonatal hyperthyroidism occurs in ~1-5% of infants born to mothers with active Graves' disease due to transplacental passage of TRAb (IgG antibodies that stimulate the fetal thyroid).
• Risk is higher if mother has high TRAb levels (>3-5 times normal), poor control, or history of neonatal thyrotoxicosis in a previous child.
• Discuss the delayed onset of neonatal thyrotoxicosis (typically day 3-10 of life) because maternal antithyroid drugs (PTU/methimazole) cross the placenta and protect the fetus in utero, but after birth the baby is exposed to TRAb without the protective effect of maternal drugs.
• Discuss clinical features: irritability, poor weight gain, tachycardia, hypertension, goiter, exophthalmos, fever, vomiting, diarrhea, failure to thrive, and rarely cardiac failure or death.
• Discuss monitoring and treatment: cord blood TFTs + TRAb, then serial TFTs in first week of life. Treatment with methimazole, propranolol, and supportive care.
• Discuss breastfeeding: PTU and methimazole are safe in breastfeeding at usual doses (PTU preferred post-partum in some guidelines due to lower breast milk transfer).
• Mention that the baby will need close follow-up by a pediatric endocrinologist.
• The examiner will then ask the candidate specific questions from the Q&A tab.
💬 Model Counseling Script – Candidate's Interaction with Mother
🗣️ Candidate's structured counseling (to be delivered to the mother):
1. Acknowledge and empathize:
“Thank you for coming in. I completely understand your worry. Having a thyroid condition yourself and being pregnant is stressful, but you are doing the right thing by planning ahead. We will make sure your baby is safe.”
2. Explain the risk (neonatal thyrotoxicosis) – but reassure:
“Because you have Graves’ disease, your body makes antibodies (called TRAb – TSH receptor antibodies) that can cross the placenta and stimulate your baby’s thyroid gland. This can cause the baby to be hyperthyroid (overactive thyroid) after birth. However, this happens in only about 1-5% of babies born to mothers with active Graves’ disease. So the chance is low, but we need to monitor carefully.”
3. Explain why symptoms appear after birth (delayed onset):
“Your antithyroid medicine (PTU) crosses the placenta and protects the baby while in the womb. That’s actually good – it prevents the baby from becoming hyperthyroid before birth. But after delivery, the medicine is cleared from the baby’s body, while the antibodies remain. That is why hyperthyroidism usually appears between day 3 and day 10 of life, sometimes as late as day 14.”
4. Discuss newborn monitoring and testing:
“Here is our plan:
• At delivery, we will take a small blood sample from the umbilical cord to check the baby’s thyroid function (TSH, free T4) and to measure the level of TRAb antibodies.
• Then, we will repeat blood tests every 2-3 days during the first week of life, and sometimes until day 14, because the problem can appear later.
• We will also monitor the baby for signs of hyperthyroidism: poor feeding, fast heart rate, irritability, weight loss, vomiting, and sometimes a swelling in the neck (goiter).”
5. Explain treatment for baby (if needed):
“If the baby becomes hyperthyroid, treatment is very effective. We use methimazole (a medicine similar to PTU) to reduce thyroid hormone production, and sometimes propranolol to control fast heart rate and irritability. Most babies need treatment for a few weeks to a few months until the mother’s antibodies disappear from their body. With treatment, babies do very well and have normal development.”
6. Discuss breastfeeding and your medicines:
“You asked about breastfeeding while taking PTU. The good news is that PTU passes into breast milk in very small amounts and is considered safe. Methimazole is also safe. The amount is far below the dose that would affect the baby. In fact, breastfeeding is encouraged because it helps bonding and provides other benefits. The only precaution is that we will monitor the baby’s thyroid function even while breastfeeding, but that is already our plan. If you prefer, some guidelines suggest using PTU during breastfeeding because it has lower milk transfer, but both are acceptable. Please continue your medicine – keeping your thyroid under control is also important for your own health and for your baby.”
7. Discuss maternal TRAb levels and future pregnancies:
“After delivery, your antibody levels will be checked. If they are high (>3 times normal), the risk for the baby is higher. For future pregnancies, we would check your TRAb level early and treat more aggressively to keep them low. Also, if you had a previous baby with neonatal thyrotoxicosis, the risk in the next baby is higher.”
8. Address her fears and provide hope:
“I know this sounds like a lot, but remember: most babies of mothers with Graves’ disease are completely healthy at birth and have no thyroid problems. We are taking precautions to detect and treat the small percentage who do. You have come to the right place, and we will work together as a team. Please do not blame yourself – you are managing your condition responsibly, and that is the best thing you can do for your baby.”
9. Summarize and close:
“To summarize: Your baby has a small risk (about 1-5%) of developing temporary hyperthyroidism after birth. We will check cord blood at delivery and repeat blood tests in the first week. If treatment is needed, it works very well. Breastfeeding is safe with your medicine. We will also involve a pediatric endocrinologist. You are doing great. Let me know if you have any more questions.”
📌 Examiner observation points (communication skills):
• Did the candidate demonstrate empathy and validate the mother’s concerns?
• Did they explain the pathophysiology in simple terms (antibodies crossing placenta)?
• Did they correctly state the risk (1-5%) without causing undue alarm?
• Did they explain the delayed onset (day 3-10) and rationale?
• Did they outline a clear plan for monitoring (cord blood + serial TFTs)?
• Did they discuss treatment options (methimazole, propranolol)?
• Did they correctly advise that breastfeeding is safe with PTU/methimazole?
• Did they mention that most babies are healthy and that transient hyperthyroidism is treatable?
• Did they refer to pediatric endocrinology?
• Did they provide reassurance and avoid judgment?
🔍 Examiner Questions (after counseling) – Click to reveal model answers
❓ Q1 (Examiner): “Explain the pathophysiology of neonatal hyperthyroidism (neonatal thyrotoxicosis) in infants born to mothers with Graves’ disease. What is the role of TRAb?”
✅ Candidate's answer:
• TRAb (TSH receptor antibodies) are IgG antibodies that bind to and stimulate the TSH receptor on the thyroid gland, causing uncontrolled thyroid hormone production.
• In mothers with active Graves' disease, high TRAb levels cross the placenta (IgG crosses easily).
• The fetal thyroid becomes stimulated by TRAb in utero, but maternal antithyroid drugs (PTU/methimazole) cross the placenta and block thyroid hormone synthesis, so the fetus is usually euthyroid or hypothyroid in utero.
• After birth, the antithyroid drugs are cleared from the neonatal circulation (half-life ~12-24 hours), but maternal TRAb persist for weeks to months (half-life ~3-4 weeks). This unopposed TRAb stimulation causes neonatal hyperthyroidism.
• Onset is typically between day 3 and day 10 of life (delayed because of residual maternal drug effect).
• The condition is self-limited once maternal TRAb are cleared (usually resolves by 3-6 months of age).
❓ Q2 (Examiner): “What are the risk factors for an infant developing neonatal hyperthyroidism? How would you identify a high-risk pregnancy?”
✅ Candidate's answer:
• Risk factors include:
- High maternal TRAb levels (>3-5 times upper limit of normal) in the third trimester.
- Poorly controlled maternal hyperthyroidism during pregnancy.
- Previous infant with neonatal hyperthyroidism (recurrence risk ~70-80%).
- Maternal history of thyroid surgery or radioiodine ablation (TRAb may remain high even if mother is euthyroid on replacement).
- Maternal Graves' disease with active ophthalmopathy or high TRAb despite treatment.
• High-risk identification: Measure maternal TRAb at 20-24 weeks and again at 28-32 weeks. Levels >3-5x normal predict high risk. Consider referral to maternal-fetal medicine.
❓ Q3 (Examiner): “What are the clinical features of neonatal hyperthyroidism? How would you suspect it in a newborn?”
✅ Candidate's answer:
• Signs and symptoms (usually appear day 3-10):
- Poor weight gain / failure to thrive (despite adequate intake).
- Irritability, jitteriness, restlessness, poor sleep.
- Tachycardia (heart rate >180-200/min at rest).
- Tachypnea, respiratory distress.
- Hypertension (systolic BP >90-100 mmHg in neonate).
- Goiter (palpable thyroid enlargement).
- Exophthalmos (protruding eyes), lid retraction, stare.
- Vomiting, diarrhea, poor feeding.
- Fever, sweating, flushing.
- Hyperreflexia, tremors.
- In severe cases: Cardiac failure, hepatosplenomegaly, jaundice, thrombocytopenia, and death if untreated.
❓ Q4 (Examiner): “What laboratory tests would you order to diagnose neonatal hyperthyroidism? What do you expect to find?”
✅ Candidate's answer:
• Cord blood (at delivery): TSH, free T4, total T4, and TRAb level. However, cord blood may be misleading due to maternal antithyroid drugs (baby may be euthyroid or hypothyroid at birth).
• Serial monitoring (days 3, 5, 7, 10, and as needed):
- TSH: Suppressed (<0.1 mIU/L).
- Free T4 and Total T4: Elevated (usually >2-3 times normal).
- TRAb: Positive and usually high (transplacental).
- T3: May be very elevated.
• Other labs: CBC, electrolytes (monitor for dehydration), liver function tests (methimazole monitoring).
• Imaging: Thyroid ultrasound (goiter, increased vascularity).
❓ Q5 (Examiner): “How do you treat a neonate with hyperthyroidism? What is the first-line medication?”
✅ Candidate's answer:
• First-line: Methimazole (MMI) (or carbimazole).
- Dose: 0.5-1.0 mg/kg/day (0.2-0.5 mg/kg/dose every 8-12 hours).
- Monitor TFTs every 2-5 days initially, then weekly.
- Adjust dose to keep free T4 in the upper half of normal range.
• Second-line (adjunctive for symptoms):Propranolol (beta-blocker) – 1-2 mg/kg/day divided every 6-8 hours – for tachycardia, hypertension, irritability.
• Severe cases (cardiac failure, extreme irritability):
- Sodium ipodate (oral cholecystographic agent) – blocks T4 to T3 conversion (rarely used).
- Lugol's iodine (potassium iodide solution) – blocks thyroid hormone release – used only short-term.
- Steroids (hydrocortisone) – inhibits T4 to T3 conversion and reduces antibody production.
• Supportive care: Adequate fluids, calories (to prevent weight loss), cooling for fever.
• Duration of treatment: Usually 1-4 months until maternal TRAb clears. Methimazole is weaned as TFTs normalize.
❓ Q6 (Examiner): “Is it safe for this mother to breastfeed while taking propylthiouracil (PTU) or methimazole? Which is preferred and why?”
✅ Candidate's answer:
• Both PTU and methimazole are considered safe in breastfeeding at usual maternal doses.
• PTU: Less is excreted into breast milk (about 0.025-0.1% of maternal dose) compared to methimazole (0.1-0.5%). However, PTU is associated with rare but serious hepatotoxicity in adults, which has not been reported in infants via breast milk.
• Current recommendations: Both are acceptable. Some guidelines prefer PTU during breastfeeding because of lower milk transfer. Others prefer methimazole because it is more effective and has fewer maternal side effects. The key is that the mother should stay on the medication that controls her own hyperthyroidism best.
• The dose in breast milk is far below the therapeutic dose for an infant (less than 1% of the infant’s therapeutic dose).
• Monitoring: The infant’s thyroid function should be monitored regardless of breastfeeding, but this is already part of the plan for at-risk infants.
• Conclusion: Encourage breastfeeding. Do not stop antithyroid medication.
❓ Q7 (Examiner): “Can antithyroid drugs (PTU/methimazole) cause hypothyroidism in the newborn? How common is it and how is it managed?”
✅ Candidate's answer:
• Yes, antithyroid drugs cross the placenta and can cause transient hypothyroidism in the fetus and newborn. This is more common if the mother is on high doses or if the drug is continued up to delivery.
• Incidence: Up to 10-15% of infants born to mothers on methimazole or PTU may have transient hypothyroidism (low T4 with normal or high TSH).
• Management:
- The hypothyroidism is usually mild and resolves spontaneously within days to weeks as the drug is cleared.
- If significant hypothyroidism (low T4 with TSH >40 mIU/L) or if the infant has symptoms (lethargy, poor feeding, prolonged jaundice), levothyroxine replacement may be started temporarily.
- TFTs are monitored weekly until normal, then levothyroxine is weaned.
- Important: This is transient, not permanent. Permanent hypothyroidism (thyroid dysgenesis) is unrelated.
• Prevention: Some endocrinologists reduce the maternal antithyroid drug dose in the last trimester to maintain the mother in a euthyroid or mildly hyperthyroid state, reducing the risk of fetal hypothyroidism.
❓ Q8 (Examiner): “What is the differential diagnosis for a neonate with tachycardia, irritability, and poor weight gain? How would you distinguish neonatal thyrotoxicosis from sepsis or other conditions?”
✅ Candidate's answer:
• Differential diagnosis:
- Neonatal sepsis (most common mimic) – fever, lethargy, poor feeding, may have elevated inflammatory markers.
- Cardiac arrhythmia (supraventricular tachycardia).
- Neonatal withdrawal (NAS) – jitteriness, irritability, but usually history of maternal substance use.
- Hypoglycemia – jitteriness, but low glucose.
- Hypocalcemia – jitteriness, tetany.
- Inborn errors of metabolism – vomiting, lethargy, acidosis.
- Neurodevelopmental disorders.
• Distinguishing features of thyrotoxicosis:
- Maternal history of Graves’ disease.
- Goiter (palpable thyroid).
- Exophthalmos or lid retraction.
- Tachycardia out of proportion to fever.
- Lab: suppressed TSH, elevated free T4/T3, positive TRAb.
- Absence of signs of infection (normal CRP, negative cultures).
• If uncertain, treat for sepsis and check TFTs simultaneously.
❓ Q9 (Examiner): “Can maternal TRAb cause fetal goiter or hydrops in utero? How is this monitored?”
✅ Candidate's answer:
• Yes, fetal hyperthyroidism can occur in utero if maternal TRAb levels are very high and antithyroid drug doses are insufficient to block the fetal thyroid.
• Fetal signs:
- Fetal goiter (detected on ultrasound – enlarged thyroid).
- Fetal tachycardia (>180 bpm).
- Intrauterine growth restriction (IUGR).
- Advanced bone age (on ultrasound – ossification centers).
- Hydrops fetalis (in severe, untreated cases) – ascites, pleural/pericardial effusions, placentomegaly – can lead to fetal demise.
• Monitoring: Serial fetal ultrasounds (every 2-4 weeks) to assess thyroid size, growth, and signs of heart failure. Umbilical blood sampling (cordocentesis) is rarely performed but can directly measure fetal TFTs.
• Management: Adjust maternal antithyroid drug dose to achieve euthyroidism in the mother and prevent fetal hyperthyroidism/goiter. If fetal goiter develops, increasing maternal antithyroid drug dose may help, but risks inducing fetal hypothyroidism.
❓ Q10 (Examiner): “How do you distinguish transient neonatal hypothyroidism caused by maternal antithyroid drugs from permanent congenital hypothyroidism (e.g., thyroid dysgenesis)?”
✅ Candidate's answer:
• Transient (maternal drug-induced):
- Positive maternal history of Graves’ disease and antithyroid drug use.
- Newborn screening may show low T4 with elevated TSH (mild to moderate).
- Normal or small thyroid gland on ultrasound (not absent).
- TFTs normalize within 1-2 weeks as the drug is cleared (without levothyroxine or with short-term levothyroxine).
- TRAb may be positive (if mother has Graves’), but this does not cause hypothyroidism.
• Permanent congenital hypothyroidism (most common: thyroid dysgenesis):
- No maternal history of thyroid disease or antithyroid drug use.
- Newborn screening shows very low T4 with high TSH (often >100 mIU/L).
- Ultrasound shows an absent, ectopic, or hypoplastic thyroid gland.
- Requires lifelong levothyroxine therapy.
- No history of maternal antithyroid drugs.
• Key step: Thyroid ultrasound and pertechnetate scan can differentiate (but often delay until after drug effect has passed). If an infant of a mother on antithyroid drugs has hypothyroidism, recheck TFTs at 2-4 weeks; if still abnormal, evaluate for permanent CH.
❓ Q11 (Examiner): “What is the recommended protocol for monitoring thyroid function in an infant born to a mother with active Graves’ disease? When should you start monitoring and for how long?”
✅ Candidate's answer:
• Cord blood at delivery: TSH, free T4, total T4, and TRAb (baseline).
• Serial monitoring (high-risk infants):
- Days 3, 5, 7, 10, and then weekly until 4-6 weeks of age or until stable.
- If infant remains asymptomatic and TFTs are normal through day 10, risk is very low, but still monitor until day 14-21 because delayed onset can occur.
• If initial TFTs are normal: Monitor weekly for first month, then at 6-8 weeks.
• If baby develops symptoms: Check TFTs immediately.
• If TRAb levels at birth are very high (>3-5x normal), monitor more closely (every 2-3 days for first 2 weeks).
• Discharge planning: Do not discharge an at-risk infant before day 5-7 without a plan for outpatient monitoring (many centers keep the infant until day 7-10 or arrange outpatient blood draws).
• Most centers recommend monitoring until at least 1-2 months of age because maternal TRAb can persist for 2-4 months.
❓ Q12 (Examiner): “What is the long-term prognosis for an infant who had neonatal hyperthyroidism? Will the child have permanent thyroid problems or developmental issues?”
✅ Candidate's answer:
• Excellent prognosis with prompt treatment.
• Thyroid function: Once maternal TRAb are cleared (usually by 3-6 months), the infant’s thyroid function returns to normal. There is no increased risk of permanent hyperthyroidism or hypothyroidism later in life unless the child develops autoimmune thyroid disease (which can happen independently but not at higher rate than general population).
• Neurodevelopment: If hyperthyroidism is recognized early and treated promptly, neurodevelopmental outcomes are normal. However, severe or untreated neonatal thyroglobulin can lead to long-term neurodevelopmental impairment (due to thyrotoxicosis).
• Long-term follow-up: The child should have a normal pediatric follow-up. There is no need for routine long-term thyroid monitoring unless symptoms develop.
• Note: The child is not at higher risk for developing Graves’ disease in childhood or adulthood than the general population (only if the mother's TRAb is not the cause – but the child's own immune system may or may not develop Graves’ later – risk is not significantly increased).
🗣️ Examiner's probing / high-yield points (Maternal Hyperthyroidism & Neonate):
• "What is the most important antibody in neonatal hyperthyroidism?" → TRAb (TSH receptor antibody).
• "What is the typical onset day of neonatal thyrotoxicosis?" → Day 3-10 of life (delayed).
• "What is the first-line treatment?" → Methimazole (0.5-1.0 mg/kg/day).
• "Is breastfeeding safe with PTU or methimazole?" → Yes, both are safe. PTU has lower milk transfer.
• "What is the risk of neonatal hyperthyroidism?" → About 1-5% in infants of mothers with active Graves' disease.
• "What is the differential diagnosis for neonatal hyperthyroidism?" → Sepsis, NAS, arrhythmia, hypoglycemia, hypocalcemia.
• "How long do TRAb persist in the infant?" → 2-4 months (half-life ~3 weeks).
• "Should you screen all infants of mothers with Graves' disease?" → Yes, with serial TFTs in the first 2 weeks.
⭐ High-yield pearls for TOACS (Maternal Hyperthyroidism Counseling):
• Most important antibody: TRAb (TSH receptor antibody).
• Onset of neonatal hyperthyroidism: Day 3-10 (not at birth).
• First-line treatment: Methimazole (NOT PTU in neonates; PTU for mother).
• Breastfeeding: Safe with both PTU and methimazole. Do not stop.
• Monitoring: Cord blood + serial TFTs in first 2 weeks.
• Differential diagnosis includes sepsis and NAS.
• Prognosis: Excellent with early treatment; transient condition.